Cargando…

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above

In women aged ≥30 years, Human Papillomavirus testing will replace cytology for primary cervical screening. We compared Hybrid Capture 2 (HC2), cobas, CLART, and APTIMA HPV assays with cytology on 2869 SurePath samples from women undergoing routine screening at 30–65 years in Copenhagen, Denmark. Wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebolj, Matejka, Bonde, Jesper, Preisler, Sarah, Ejegod, Ditte, Rygaard, Carsten, Lynge, Elsebeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720421/ https://www.ncbi.nlm.nih.gov/pubmed/26789267 http://dx.doi.org/10.1371/journal.pone.0147326

Ejemplares similares

Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening
por: Rebolj, Matejka, et al.
Publicado: (2014)

Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays
por: Rebolj, Matejka, et al.
Publicado: (2016)

Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study
por: Preisler, Sarah, et al.
Publicado: (2016)

Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay
por: Preisler, Sarah, et al.
Publicado: (2013)

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system
por: Bonde, Jesper, et al.
Publicado: (2014)

Human papillomavirus self‐sampling for screening nonattenders: Opt‐in pilot implementation with electronic communication platforms
por: Lam, Janni Uyen Hoa, et al.
Publicado: (2017)

Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review
por: Rebolj, Matejka, et al.
Publicado: (2011)

Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark
por: Rebolj, Matejka, et al.
Publicado: (2015)

Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study
por: Ejegod, Ditte Møller, et al.
Publicado: (2015)

High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders
por: Lam, J U H, et al.
Publicado: (2018)

Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders
por: Lam, J. U. H., et al.
Publicado: (2017)

The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
por: Ejegod, Ditte, et al.
Publicado: (2016)

Is a delay in the introduction of human papillomavirus-based cervical screening affordable?
por: Castañon, Alejandra, et al.
Publicado: (2018)

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework
por: Bonde, Jesper Hansen, et al.
Publicado: (2020)

Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60–64 Years
por: Schroll, Jeppe Bennekou, et al.
Publicado: (2021)

Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2019)

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening
por: Ejegod, Ditte Møller, et al.
Publicado: (2020)

Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program
por: Ejegod, Ditte Møller, et al.
Publicado: (2021)

Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening
por: Ejegod, Ditte Møller, et al.
Publicado: (2018)

Incidence of cervical cancer after several negative smear results by age 50: prospective observational study
por: Rebolj, Matejka, et al.
Publicado: (2009)

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
por: Dillner, Joakim, et al.
Publicado: (2008)

Impact of HPV vaccination on outcome of cervical cytology screening in Denmark—A register‐based cohort study
por: Thamsborg, Lise Holst, et al.
Publicado: (2018)

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
por: Lynge, Elsebeth, et al.
Publicado: (2020)

Danish method study on cervical screening in women offered HPV vaccination as girls (Trial23): a study protocol
por: Thamsborg, Lise Holst, et al.
Publicado: (2018)

Conization and healthcare use: a population-based register study
por: Frederiksen, Maria E., et al.
Publicado: (2019)

Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening
por: Rebolj, M, et al.
Publicado: (2010)

COVID-19 disruption to cervical cancer screening in England
por: Castanon, Alejandra, et al.
Publicado: (2022)

The Danish Quality Database for Cervical Cancer Screening
por: Rygaard, Carsten
Publicado: (2016)

Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses
por: Castanon, Alejandra, et al.
Publicado: (2021)

Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review
por: Bonde, Jesper, et al.
Publicado: (2020)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework
por: Bhatia, Ramya, et al.
Publicado: (2023)

High‐grade cervical lesions after vaccination against human papillomavirus: A Danish cohort study
por: Thamsborg, Lise Holst, et al.
Publicado: (2020)

Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study
por: Rozemeijer, Kirsten, et al.
Publicado: (2017)

Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan
por: Sasaki, Yuri, et al.
Publicado: (2017)

Concurrent participation in breast, cervical, and colorectal cancer screening programmes in Denmark: A nationwide registry-based study
por: Njor, Sisse Helle, et al.
Publicado: (2023)

Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review
por: Bonde, Jesper H., et al.
Publicado: (2019)

Primary cervical screening with high risk human papillomavirus testing: observational study
por: Rebolj, Matejka, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uvia9468g5gjl0ask9tf33co1c